Current Trends in the Treatment of Polycystic Ovary Syndrome with Desire for Children

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2009 Jun 19

PMID 19536311

Citations 5

Authors

Margalida E Sastre

Maria O Prat

Miguel Angel Checa

Ramon C Carreras

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS), one of the most frequent endocrine diseases, affects approximately 5%-10% of women of childbearing age and constitutes the most common cause of female sterility regardless of the need or not for treatment, a change in lifestyle is essential for the treatment to work and ovulation to be restored. Obesity is the principal reason for modifying lifestyle since its reduction improves ovulation and the capacity for pregnancy and lowers the risk of miscarriage and later complications that may occur during pregnancy (gestational diabetes, pre-eclampsia, etc). When lifestyle modification is not sufficient, the first step in ovulation induction is clomiphene citrate. The second-step recommendation is either exogenous gonadotrophins or laparoscopic ovarian surgery. Recommended third-line treatment is in vitro fertilization. Metformin use in PCOS should be restricted to women with glucose intolerance.

Citing Articles

Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome.

Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W Front Endocrinol (Lausanne). 2021; 12:741764.

PMID: 34745009 PMC: 8564180. DOI: 10.3389/fendo.2021.741764.

A combination of spearmint and flaxseed extract improved endocrine and histomorphology of ovary in experimental PCOS.

Mehraban M, Jelodar G, Rahmanifar F J Ovarian Res. 2020; 13(1):32.

PMID: 32197626 PMC: 7085145. DOI: 10.1186/s13048-020-00633-8.

Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.

Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I Endocrine. 2013; 44(3):583-90.

PMID: 23625194 DOI: 10.1007/s12020-013-9971-5.

Treatment options for polycystic ovary syndrome.

Badawy A, Elnashar A Int J Womens Health. 2011; 3:25-35.

PMID: 21339935 PMC: 3039006. DOI: 10.2147/IJWH.S11304.

Insulin and hyperandrogenism in women with polycystic ovary syndrome.

Baptiste C, Battista M, Trottier A, Baillargeon J J Steroid Biochem Mol Biol. 2009; 122(1-3):42-52.

PMID: 20036327 PMC: 3846536. DOI: 10.1016/j.jsbmb.2009.12.010.

References

Polson D, Adams J, Wadsworth J, Franks S . Polycystic ovaries--a common finding in normal women. Lancet. 1988; 1(8590):870-2. DOI: 10.1016/s0140-6736(88)91612-1. View

Holte J, Bergh T, Berne C, Wide L, Lithell H . Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995; 80(9):2586-93. DOI: 10.1210/jcem.80.9.7673399. View

Seli E, Duleba A . Should patients with polycystic ovarian syndrome be treated with metformin?. Hum Reprod. 2002; 17(9):2230-6. DOI: 10.1093/humrep/17.9.2230. View

Crosignani P, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G . Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003; 18(9):1928-32. DOI: 10.1093/humrep/deg367. View

Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A . Obesity and reproductive disorders in women. Hum Reprod Update. 2003; 9(4):359-72. DOI: 10.1093/humupd/dmg024. View

Mulders A, Laven J, Eijkemans M, Hughes E, Fauser B . Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta-analysis. Hum Reprod Update. 2003; 9(5):429-49. DOI: 10.1093/humupd/dmg035. View

Filicori M, Cognigni G, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli de Fatis C . Luteinzing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab. 2001; 86(1):337-43. DOI: 10.1210/jcem.86.1.7108. View

Christin-Maitre S, Hugues J . A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod. 2003; 18(8):1626-31. DOI: 10.1093/humrep/deg336. View

Dickey R, Taylor S, Curole D, Rye P, Pyrzak R . Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod. 1996; 11(12):2623-8. DOI: 10.1093/oxfordjournals.humrep.a019182. View

10.

Genazzani A, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O . Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004; 81(1):114-9. DOI: 10.1016/j.fertnstert.2003.05.020. View

11.

Kocak M, Caliskan E, Simsir C, Haberal A . Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril. 2002; 77(1):101-6. DOI: 10.1016/s0015-0282(01)02941-7. View

12.

Weiss J, Malone F, Emig D, Ball R, Nyberg D, Comstock C . Obesity, obstetric complications and cesarean delivery rate--a population-based screening study. Am J Obstet Gynecol. 2004; 190(4):1091-7. DOI: 10.1016/j.ajog.2003.09.058. View

13.

Moran L, Brinkworth G, Noakes M, Norman R . Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online. 2006; 12(5):569-78. DOI: 10.1016/s1472-6483(10)61182-0. View

14.

. Ovarian hyperstimulation syndrome. Fertil Steril. 2006; 86(5 Suppl 1):S178-83. DOI: 10.1016/j.fertnstert.2006.08.021. View

15.

Carroll N, Palmer J . A comparison of intrauterine versus intracervical insemination in fertile single women. Fertil Steril. 2001; 75(4):656-60. DOI: 10.1016/s0015-0282(00)01782-9. View

16.

Legro R, Kunselman A, Dodson W, Dunaif A . Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84(1):165-9. DOI: 10.1210/jcem.84.1.5393. View

17.

Homburg R, Howles C . Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update. 1999; 5(5):493-9. DOI: 10.1093/humupd/5.5.493. View

18.

GJONNAESS H . Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scand. 1994; 73(5):407-12. DOI: 10.3109/00016349409006253. View

19.

Jakubowicz D, Nestler J . 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab. 1997; 82(2):556-60. DOI: 10.1210/jcem.82.2.3753. View

20.

Rimington M, Walker S, Shaw R . The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod. 1997; 12(7):1443-7. DOI: 10.1093/humrep/12.7.1443. View